Abstract
Despite the widespread use of anti-retroviral therapy, human immunodeficiency virus (HIV) still persists in an infected cell reservoir that harbors transcriptionally silent yet replication-competent proviruses. While significant progress has been made in understanding how the HIV reservoir is established, transcription repression mechanisms that are enforced on the integrated viral promoter have not been fully revealed. In this study, we performed a whole-genome CRISPR knockout screen in HIV infected T cells to identify host genes that potentially promote HIV latency. Of several top candidates, the KRAB-containing zinc finger protein, ZNF304, was identified as the top hit. ZNF304 silences HIV gene transcription through associating with TRIM28 and recruiting to the viral promoter heterochromatin-inducing methyltransferases, including the polycomb repression complex (PRC) and SETB1. Depletion of ZNF304 expression reduced levels of H3K9me3, H3K27me3 and H2AK119ub repressive histone marks on the HIV promoter as well as SETB1 and TRIM28, ultimately enhancing HIV gene transcription. Significantly, ZNF304 also promoted HIV latency, as its depletion delayed the entry of HIV infected cells into latency. In primary CD4+ cells, ectopic expression of ZNF304 silenced viral transcription. We conclude that by associating with TRIM28 and recruiting host transcriptional repressive complexes, SETB1 and PRC, to the HIV promoter, ZNF304 silences HIV gene transcription and promotes viral latency.
Highlights
The introduction of antiretroviral therapy (ART) has limited the spread of the human immunodeficiency virus (HIV) and has significantly improved the clinical outcomes associated with this viral infection
A complete cure remains out of reach, as HIV persists in a cell reservoir that is highly stable in the face of therapy
We identified zinc-finger protein 304 (ZNF304) and showed that through association with TRIM28, it recruits the histone methyltransferases SETB1 and polycomb repression complex (PRC) to deposit
Summary
The introduction of antiretroviral therapy (ART) has limited the spread of the human immunodeficiency virus (HIV) and has significantly improved the clinical outcomes associated with this viral infection. One approach that has been suggested for eliminating the HIV reservoir is the “shock-and-kill” strategy, which employs latency-reversing agents (LRAs) to activate resting infected cells, exposing them to the immune system and to the effects of ART [19,20,21,22,23]. This approach, which is based on the successful use of LRAs as modulators of chromatin architecture, has, regretfully failed to display clinical efficacy in vivo, thereby prompting the search for alternative therapies [16, 24,25,26]. Despite considerable progress, new and improved strategies for eradicating the HIV reservoir remain out of reach, and the pathways governing proviral silencing are yet to be fully understood [1, 27]
Published Version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have